<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943420</url>
  </required_header>
  <id_info>
    <org_study_id>BE2017770</org_study_id>
    <nct_id>NCT03943420</nct_id>
  </id_info>
  <brief_title>One Research on Improving Cognitive Impairment Caused by Hypertension</brief_title>
  <official_title>One Research on Application of Key Technologies About Improving Cognitive Impairment Caused by Hypertension With the Therapy of Early Intervention With Qianyang Yuyin Granules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Famous Medical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Famous Medical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using the therapy of early intervention with Qianyang Yuyin Granules to improve cognitive&#xD;
      impairment caused by hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using the therapy of early intervention with Qianyang Yuyin Granules to improve cognitive&#xD;
      impairment caused by hypertension.&#xD;
&#xD;
      The investigators designed a multi-center randomized controlled clinical trial to study the&#xD;
      security and effectiveness of this therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 28, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Changes of brain image</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measure and record the volume changes of diseased alba, the micro-structure changes of alba fasciculus by MRI to see if the therapy effect or not.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure and assess the changes of VaDAS-cog ( Vascular Dementia Assessment Scale cognitive subscale ) among time points</measure>
    <time_frame>12 weeks, 24 weeks, 48 weeks</time_frame>
    <description>Measure and record with VaDAS-cog</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure and assess the changes of MMSE ( Mini-mental State Examination ) among time points</measure>
    <time_frame>12 weeks, 24 weeks, 48 weeks</time_frame>
    <description>Measure and record with MMSE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure and assess the changes of ADL ( Activity of Daily Living ) among time points</measure>
    <time_frame>12 weeks, 24 weeks, 48 weeks</time_frame>
    <description>Measure and record with ADL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure and assess the changes of CDR ( Clinical Dementia Rating ) among time points</measure>
    <time_frame>12 weeks, 24 weeks, 48 weeks</time_frame>
    <description>Measure and record with CDR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of outcome event</measure>
    <time_frame>24 weeks</time_frame>
    <description>Record the outcome event and analyse the incidence rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic effect</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measure and record patients' systolic and diastolic blood pressure and analyse related data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabonomics</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measure and record the metabonomics ( Trx &amp; TrxR ) index</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <description>Therapy A : Basic treatment + Qianyang Yuyin Granules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Control Group</arm_group_label>
    <description>Therapy B : Basic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive Control Group</arm_group_label>
    <description>Therapy C : Basic treatment + Donepezil</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample; Urine sample.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cognitive impairment caused by hypertension.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 55 to 75 years old, male or female;&#xD;
&#xD;
          -  Having a history of hypertension for more than 2 years but can maintain SBP ≤ 140 mmHg&#xD;
             and BDP ≤ 90 mmHg with medication；&#xD;
&#xD;
          -  21 ≤ MMSE &lt; 26, or 14 ≤ MoCA &lt; 26, CDR &lt; 0.5. Bseides, the chief complaint must happen&#xD;
             after having hypertension；&#xD;
&#xD;
          -  Meet TCM Syndrome Differentiation Standard：according to the Guidelines for the&#xD;
             Clinical Research of Chinese Medicine New Drugs ( published by China Medical Science&#xD;
             Press ) ：Overabundant liver-fire type：dizziness and headache, both face and eyes are&#xD;
             red, dry mouth and bitter taste in mouth, red tongue with yellowish coating, wire and&#xD;
             frequent pulse. Yin deficiency and yang hyperactivity type: dizziness and headache,&#xD;
             Tinnitus and forgetfulness, sphoria with feverish sensation in chest &amp; palms &amp; soles,&#xD;
             palpitation and insomnia, red tongue &amp; thin white or less coating, wiry weak and&#xD;
             numbered pulse；&#xD;
&#xD;
          -  CTMRI hint: leukoaraiosis and no sign of Cerebral infarction；&#xD;
&#xD;
          -  Patients or the guardian hold the right opinions over the research and are willing to&#xD;
             obey researcher's orders；&#xD;
&#xD;
          -  Having a certain degree of education (being able to read simple newspapers in the&#xD;
             past)；&#xD;
&#xD;
          -  Patients agree to sign informed consent。&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary hypertension；&#xD;
&#xD;
          -  Taking certain kinds of antihypertensive drugs which may damage brain cognitive&#xD;
             function；&#xD;
&#xD;
          -  Diagnosed as depression or other mental disorders according to DSM-IV；&#xD;
&#xD;
          -  Diagnosed as vascular dementia according to diagnostic criteria, CDR ≥ 0.5; alzheimer&#xD;
             disease or dementia caused by some other reasons (including mixed dementia according&#xD;
             to diagnostic criteria for VCI); cognitive impairment due to head injury。&#xD;
&#xD;
          -  Suffering from certain kinds of diseases which may interfere the assessment of&#xD;
             cognitive function, including those who are diagnosed as alcoholics and drugs or&#xD;
             psychotropic medicine abusers during the last 5 years according to DSM-IV；&#xD;
&#xD;
          -  Accompanied with severe neurological function disorder；&#xD;
&#xD;
          -  Asthma, chronic severe primary cardiovascular disease, liver lesion, hematological&#xD;
             lesions, lung diseases, diabetes or other severe diseases may influence the patients'&#xD;
             survival such as cancer or AIDS；&#xD;
&#xD;
          -  Other: Such as poor compliance, or can not attend the follow-up visit in time for some&#xD;
             reasons；&#xD;
&#xD;
          -  Taking the same kind of medicine during the last 30 days which may influence the&#xD;
             trial；&#xD;
&#xD;
          -  Is participating in another clinical study；&#xD;
&#xD;
          -  Not up to TCM Syndrome Differentiation Standard。&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cheng Chang, PhD</last_name>
    <phone>+8613851821996</phone>
    <email>chch1967@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jiangsu Province Hospital of Chinese Medcine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Chang, PhD</last_name>
      <phone>+8613851821996</phone>
      <email>chch1967@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Therapy</keyword>
  <keyword>Qianyang Yuyin Granules</keyword>
  <keyword>Cognitive impairment</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

